Shares of Paratek Pharmaceuticals (NASDAQ: PRTK) flew nearly 20% higher on Tuesday, on an otherwise forgettable day for the stock market. There was little mystery why -- the company won another approval for its next-generation antibiotic Nuzyra.
Paratek announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (NDA) for the oral-only formulation of Nuzyra to treat adults suffering from community-acquired bacterial pneumonia (CABP), a lung disease.
Image source: Getty Images.
For further details see:
Why Paratek Pharmaceuticals Crushed the Market Today